- Alzamend Neuro tackles Alzheimer’s, BD, MDD and PTSD with breakthrough therapies.
- AL001 delivers improved brain targeting and fewer side effects than lithium carbonate.
- Phase II trials underway with support from Mass General and AI partner QMENTA.
- ALZN002 offers a novel, adjuvant-free immunotherapy for Alzheimer’s disease.
Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory™,” the Atlanta-based company is advancing a robust pipeline of therapies aimed at delivering long-overdue innovation in safety, efficacy, and tolerability. Rather than tweaking existing treatments, Alzamend is engineering bold new approaches that directly address the limitations of current standards of care.
Leading its portfolio is AL001, a patented ionic cocrystal formulation of lithium designed to penetrate the brain more effectively while reducing systemic side effects. In partnership with Massachusetts General Hospital and imaging partner QMENTA, the company launched the first of five Phase II trials in 2025, evaluating lithium distribution using next-generation imaging tools. Alzamend’s broader platform is backed by exclusive licenses from the University of South Florida and leverages strategic alliances with both academic and technological leaders.
The company is also advancing ALZN002, a personalized immunotherapy for Alzheimer’s that uses the patient’s own dendritic cells to generate a targeted response to amyloid-beta plaque — a hallmark of the disease. While paused in early 2024, the Phase I/IIA trial is expected to resume in 2025. Early data have shown promising immune responses without triggering inflammatory side effects, offering a potential path toward disease-modifying treatment — a longstanding unmet need in Alzheimer’s care.
With over 43 million Americans and 660 million people worldwide living with conditions targeted by its pipeline, Alzamend is operating at the intersection of urgent need and massive market potential. Its leadership team, drawn from major biopharma and financial firms, is steering the company through this critical growth phase with a focus on execution and long-term value. As costs for Alzheimer’s and related disorders continue to surge — projected to top $1.1 trillion by 2050 — Alzamend’s differentiated therapies and strong clinical momentum position it as a company to watch in both neuroscience and mental health innovation.
NOTE TO INVESTORS: The latest news and updates relating to ALZN are available in the company’s newsroom at https://ibn.fm/ALZN
